Sonrai and AOA Dx partner to accelerate ovarian cancer test development

Strategic collaboration aims to improve early diagnosis

Sonrai Analytics and AOA Dx have announced a partnership to accelerate the development of AOA’s multi-omic liquid biopsy test for ovarian cancer. The collaboration will use Sonrai’s AI-powered platform to validate diagnostic biomarkers, improving accuracy and clinical utility.

AOA will integrate Sonrai’s cloud-based analytics platform to analyse multi-modal data, including multi-omic and clinical information. The test uses a combination of gangliosides, lipids, and proteins to diagnose ovarian cancer in women experiencing vague abdominal symptoms. Early diagnosis could significantly improve patient outcomes while reducing healthcare costs.

Sonrai will provide bioinformatics expertise, offering machine learning tools and automated data pipelines in a secure environment. The Sonrai Discovery platform will allow AOA to store and manage clinical data with controlled access and real-time performance tracking.

Prof Darragh McArt, CEO and founder of Sonrai Analytics, said: “We’re delighted to partner with AOA Dx to help advance the development of their innovative test for ovarian cancer. By applying our AI-powered analytics platform, we’re able to unlock deeper insights from complex multi-modal data, accelerating the validation of biomarkers, enabling earlier and more accurate detection.”

Dr Abigail McElhinny, chief scientific officer at AOA Dx, said: “By partnering with Sonrai, we can not only integrate and manage our in-house development data but also cross-reference it with public datasets and analyse it seamlessly within one centralised environment.”

The collaboration aims to improve ovarian cancer diagnostics and provide more effective tools for early detection, supporting innovation in precision medicine